Information Provided By:
Fly News Breaks for January 21, 2020
Jan 21, 2020 | 07:47 EDT
Guggenheim analyst Yatin Suneja raised Zogenix's price target to $78 from $64 and reiterates a Buy rating on the shares. Following a review of competitor data and key opinion leader feedback, the analyst is positive into the upcoming Phase III Study 1601 evaluating Fintepla in Lennox-Gastaut syndrome. Suneja sees a potential up 30%, down 50% move in the stock on these data. Further, fintepla has demonstrated "robust" efficacy in Dravet syndrome patients with approval likely in this indication by March 25, Suneja tells investors in a research note
News For ZGNX From the Last 2 Days
Apr 19, 2021 | 09:24 EDT
73rd Annual Virtual Meeting of AAN will be held on April 17-22. Webcast Link